瑞倍三联疗法根除幽门螺杆菌的临床研究  

Clinical Effectiveness of Ranitidine Bismuth Citrate Based Triple Therapy for Eradicating Helicobacter Pylori

作　　者：王作然[1] 吴丽颖[1] 凌明德[1] 

机构地区：[1]安徽省淮北市人民医院消化科安徽省淮北市人民医院消化疾病研究室,淮北235000

出　　处：《临床消化病杂志》2007年第1期33-34,39,共3页Chinese Journal of Clinical Gastroenterology

摘　　要：目的观察以枸橼酸铋雷尼替丁(Ranitidine Bismuth Citrate,RBC瑞倍)为基础的三联疗法对幽门螺杆菌(Hp)根除疗效及安全性。方法将确诊为Hp阳性147例患者随机分为3组,即瑞倍组、奥美拉唑组和雷尼替丁组,疗程1周,应用14C-尿素呼气试验及荧光定量PCR法检测Hp-DNA判断Hp根除效果。结果根据意图分析治疗(ITT)分析Hp根除率分别为瑞倍组83.7%、奥美拉唑组87.5%、雷尼替丁组70%。根据试验方案分析(PP)Hp根除率分别为87.2%、93.3%及72.9%。瑞倍组Hp根除率与奥美拉唑组相近,但2组均较雷尼替丁组明显升高。瑞倍组和奥美拉唑组较雷尼替丁组消化道症状明显改善,但瑞倍组与奥美拉唑2组间无明显差异。瑞倍组与奥美拉唑组不良反应均较雷尼替丁组轻微。结论瑞倍三联疗法根除Hp的临床疗效优于雷尼替丁三联疗法,但与奥美拉唑三联疗法相当,副反应发生情况也与奥美拉唑三联疗法无显著性差异,且因瑞倍相对价格低廉,值得作为一线药物推广应用。Objective To study the saety and effectiveness of ranitidine bismuth citrate（RBC） based triple therapy in eradicating Helico- bacter pylori（Hp）. Methods 147 patients with Hp-positive were randomly divided into 3 greups：RBC therapy group, Omeprazole therapy group and Ranitidin therapy group. Hp eradication was assessed by 14C-urea breath test and real-time quantitative PCR 4 weeks after completion of 1 week triple therapy regimen. Results The intent-to-treat（liT） and per-protocol（PP） eradieation rates were statistiealy equivalent between RBC group （ 83. 7 % ITT,87. 2% PP） and omeprazole group （ 87. 5 % ITT,93. 3 % PP ）. Incidence of adverse events and improvement of symptoms did not differ between the above two groups. However, the eradication rates in RBC group were higher than that in Ranitidine group significantly. Incidence of adverse events in RBC group was lower than that in Ranitidine group. Conclusion The clinical effect of RBC based one week triple therapy is similar to Omeprazole triple therapy and better than Ranitidine triple therapy. Therefore, it is recommended as the first-line regiment for eradieaing Hp.

关 键 词：瑞倍 幽门螺杆菌 奥美拉唑 雷尼替丁 三联疗法 

分 类 号：R57[医药卫生—消化系统]